

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

1. (original) A DNA segment encoding a human type α PDGF receptor protein.
2. (original) A DNA segment according to claim 1, wherein said segment comprises genomic clone T11 or cDNA clone TR4.
3. (original) A DNA segment, according to claim 1, wherein said protein has the amino acid sequence defined in Figure 3.
4. (original) A recombinant DNA molecule comprising a DNA segment according to claim 1 and a vector.
5. (original) A culture of cells transformed with a DNA segment according to claim 1.
6. (original) A method of producing a human type α PDGF receptor protein comprising culturing cells according to claim 5 under conditions such that said protein is produced and isolating said protein from said cells.
7. (original) A human type α PDGF receptor protein having the amino acid sequence defined in Figure 3.
8. (original) An antibody specific for a protein having the amino acid sequence of a type α human PDGF receptor protein, according to claim 7.

9. (original) An antibody according to claim 8, wherein said antibody is specific for only a type α PDGF receptor protein.
10. (original) An antibody specific for a protein having the amino acid sequence of a type β human PDGF receptor protein, wherein said antibody is specific for only a type β human PDGF receptor protein.
11. (original) A bioassay for expression of a type α PDGF receptor gene comprising the steps of:
- i) contacting a biological sample suspected of containing RNA with a DNA probe comprising a DNA segment according to claim 1, under conditions such that a DNA:RNA hybrid molecule containing said DNA probe and complementary RNA is formed; and
 - ii) determining the amount of said DNA probe present in said hybrid molecules.
12. (original) A bioassay for a type α PDGF receptor antigen comprising the steps of:
- i) contacting a biological sample suspected of containing polypeptides with an antibody according to claim 8, under conditions such that a specific complex of said antibody and said antigen is formed; and
 - ii) determining the amount of said antibody in said complexes.
13. (original) A bioassay for type β PDGF receptor antigen comprising the steps of:
- i) contacting a biological sample suspected of containing polypeptides with an antibody according to claim 10, under conditions such that a specific complex of said antibody and said antigen is formed; and
 - ii) determining the amount of said antibody in said complexes.

14. (new) A method of evaluating binding affinity of a test compound to α PDGF receptor, said method comprising the steps of:

a) contacting a sample containing said receptor with

(i) the monoclonal antibody or fragment thereof of claim 8; and

(ii) said test compound;

b) measuring the amount of said monoclonal antibody or fragment thereof, said amount being inversely proportional to the amount of test compound which bound to said receptor.